

A Comprehensive and Robust Multiplex-DIA Workflow Profiles Protein Turnover Regulations Associated with Cisplatin Resistance

Barbora Salovska^{1,2}, Wenxue Li^{1,2}, Oliver M. Bernhardt³, Pierre-Luc Germain⁴, Tejas Gandhi³, Lukas Reiter³, Yansheng Liu^{1,2,5*}

1. Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA.
2. Cancer Biology Institute, Yale University School of Medicine, West Haven, CT 06516, USA.
3. Biognosys Zurich-Schlieren, Switzerland.
4. Institute for Neuroscience, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.
5. Department of Biomedical Informatics & Data Science, Yale University School of Medicine, New Haven, CT 06510, USA.

*Corresponding author: Yansheng Liu (Email: Yansheng.liu@yale.edu, Tel: +1 203-737-3853)

1 Summary

2 Measuring protein turnover is essential for understanding cellular biological processes and
3 advancing drug discovery. The multiplex DIA mass spectrometry (DIA-MS) approach, combined with
4 dynamic SILAC labeling (pulse-SILAC, or pSILAC), has proven to be a reliable method for analyzing
5 protein turnover and degradation kinetics. Previous multiplex DIA-MS workflows have employed various
6 strategies, including leveraging the highest isotopic labeling channels of peptides to enhance the detection
7 of isotopic MS signal pairs or clusters. In this study, we introduce an improved and robust workflow that
8 integrates a novel machine learning strategy and channel-specific statistical filtering, enabling dynamic
9 adaptation to systematic or temporal variations in channel ratios. This allows comprehensive profiling of
10 protein turnover throughout the pSILAC experiment without relying solely on the highest channel signals.
11 Additionally, we developed *KdeggeR*, a data processing and analysis package optimized for pSILAC-DIA
12 experiments, which estimates and visualizes peptide and protein degradation rates and dynamic profiles.
13 Our integrative workflow was benchmarked on both 2-channel and 3-channel standard DIA datasets and
14 across two mass spectrometry platforms, demonstrating its broad applicability. Finally, applying this

15 workflow to an aneuploid cancer cell model before and after cisplatin resistance development
16 demonstrated a strong negative correlation between transcript regulation and protein degradation for major
17 protein complex subunits. We also identified specific protein turnover signatures associated with cisplatin
18 resistance.

19 **Keywords**

20 Multiplex DIA, Mass spectrometry, pulse SILAC, DIA, Protein turnover, Drug resistance, Aneuploidy

21 **Introduction**

22 Protein turnover, the balance between synthesis and degradation, is a fundamental process that
23 regulates cellular homeostasis, adaptation, and response to environmental stimuli. It plays a crucial role
24 in a variety of biological processes, including cell growth, differentiation, and apoptosis, and is a critical
25 factor in understanding disease progression and therapeutic responses. In cancer biology, for example,
26 altered protein turnover rates are often linked to genomic instability, such as aneuploidy, and resistance to
27 chemotherapeutic agents like cisplatin^{1,2}. Understanding the dynamics of protein turnover in these
28 contexts is essential for identifying potential therapeutic targets and biomarkers.

29 Mass spectrometry (MS)-based approaches have become a key tool for studying protein turnover,
30 with data-independent acquisition (DIA) MS being one of the most robust and reproducible techniques^{3,4}.
31 The multiplex DIA-MS approach, when combined with dynamic stable isotope labeling by amino acids
32 in cell culture (pulse-SILAC, or pSILAC)⁵⁻⁸, allows for multi-time-point measurements and the precise
33 quantification of protein-specific turnover rates across diverse biological conditions⁹⁻¹⁴. Its ability to
34 profile large numbers of peptides and proteomes reproducibly makes DIA-MS particularly well-suited for
35 complex experimental designs, such as time-course experiments often used in dynamic SILAC design.

36 Recent advancements in MS acquisition strategies have further enhanced the power and
37 throughput of DIA-MS workflows. Techniques such as BoxCarMax¹⁵, which involves small isolation
38 windows in combination with multiple runs, and instruments like Astral¹⁶ and timsTOF, which support
39 small isolation windows directly, have significantly improved the peptide detection and quantification of
40 heavy (H) and light (L) ratios. These advancements increase the precision and depth of protein turnover
41 analysis.

42 A particular challenge that pSILAC experiments face is that the intensity of the channels mirrors
43 the protein turnover rate which can lead to a near absence of one of the channels for a particular protein
44 (or peptide) in the early and very late time points. Previous strategies have relied on focusing on specific
45 channels: We previously presented an Inverted Spike-In Workflow (ISW)¹⁰ which utilizes only the light
46 channel for scoring and signal detection in pSILAC-DIA data, increasing the number of H/L pairs being
47 measured by ca. 30% in early pSILAC labeling time points. However, ISW is not ideal for the late pSILAC
48 labeling time points and other multiplex DIA-MS experiments in which the labeled peptide signals are
49 often higher than the light ones depending on the specific experimental condition and individual proteins.
50 On the other hand, strategies such as plex-DIA¹⁷ or mDIA¹⁸ utilize DIA-NN¹⁹ or RefQuant¹⁸ software
51 tools to target the highest isotopic channel or the reference channel for improving peptide detection. These
52 approaches, while effective, still leave room for optimization, in e.g., leveraging all available isotopic
53 channels and peptide transitions for more comprehensive protein turnover quantification.

54 Herein, we introduce a novel approach that incorporates machine learning and channel-specific
55 statistical filtering into the peptide detection process in multiplex DIA datasets. Our method dynamically
56 adapts to systematic changes in isotopic channel ratios, ensuring that all channels are effectively utilized
57 without the need of selecting the highest signals. We extensively assessed this improvement and found
58 that, together with a following data processing tool, the accuracy and robustness of protein turnover
59 measurements in complex pSILAC datasets were significantly enhanced.

60 To apply our enhanced workflow, we focused on an aneuploidy cancer cell model. Aneuploidy,
61 characterized by an abnormal number of chromosomes, alters the protein homeostasis landscape, leading
62 to unique turnover profiles that may contribute to the development of resistance to drugs. Our pSILAC-
63 DIA measurement and workflow applied in the aneuploidy ovarian cells divergent for cisplatin resistance
64 uncovered key turnover signatures and regulations that potentially drive resistance mechanisms, providing
65 new insights into potential therapeutic strategies.

66 Results

67 Overview of a Robust Workflow for Multiplex-DIA MS Data Analysis Enabling Large-Scale 68 Protein Turnover Quantification and Comparative Studies

69 Multiplex-DIA-MS, combined with pSILAC enables precise quantification of protein turnover
70 across multiple conditions by measuring protein dynamics at different time points (**Figure 1, Upper left**).
71 However, effectively detecting and quantifying MS signals in multiplex pSILAC-DIA datasets in which
72 the heavy signal might be low abundant in the early labeling time points remains challenging. To address
73 this challenge, we previously introduced the “Inverted Spike-In workflow” (ISW)¹⁰. In that work, we
74 firstly relied on an extensive hybrid library generated using label-free and multiplexed samples, both
75 DDA-MS and DIA-MS. This library was then used to perform a targeted extraction of the multiplexed
76 DIA-MS raw files, employing the ISW workflow, **Figure 1, Lower left**). In ISW, the peak picking and
77 scoring are based exclusively on the “light” precursors, which we demonstrated as advantageous in
78 samples with a low relative abundance of “heavy” signals such as extreme H/L dilutions¹⁵ or early
79 labeling time points of a pSILAC experiment¹⁰.

80 However, recent rapid advancements in library-free DIA-MS data analysis in software such as the
81 directDIA algorithm in Spectronaut²⁰ and other software tools like DIA-NN¹⁹, or FragPipe²¹, driven by
82 machine learning and deep learning techniques, have essentially eliminated the need to generate extensive
83 project-specific spectral libraries for routine peptide identifications in proteomics, significantly
84 streamlining DIA-MS data analysis. Additionally, we reason that performing the XIC peak picking and
85 elution group scoring using the information across all channels ($n = 2, 3, \dots, n$) may enable a more dynamic
86 scoring of increasingly complex labeling experiments, accommodating a wider range of labeled/unlabeled
87 ratios over the entire experiment and additional labeling channels (see Introduction).

88 Leveraging the directDIA algorithm and improved machine learning, we optimized and evaluated
89 a library-free “Labeled” workflow (LBL), which is available in Spectronaut v19 (**Figure 1 – Lower left**).
90 Notably, during the targeted peak extraction, this workflow performs the XIC peak picking across all
91 channels in a combined fashion. Moreover, in the elution group scoring, all channels, along with their
92 specific and cross-channel scores, are considered collectively in the machine learning process, leading to
93 an estimation of a “Group Q-value”. Together, these allow for dynamic adaptation to systematic changes
94 in channel ratios per sample, leading to the optimal scoring weights of the labeled and unlabeled peptide

95 transitions consistent with the SILAC ratios in real pSILAC experiments (**Figure 1 – Upper Middle**).
96 Additionally, labeled or unlabeled channels can be also scored independently based on channel-specific
97 metrics, supporting the determination of channel-specific Q-values, which is newly possible with
98 Spectronaut v19. This further enables channel-specific FDR filtering of the quantification results. In the
99 “Min Q-value” option, at least one channel needs to be independently identified (Q value < 0.01), while
100 in the “Max Q-value” option, all channels must be independently identified to accept the entire elution
101 group for a given peptide (**Figure 1 – Upper Middle**). To evaluate the sensitivity, quantification precision,
102 and accuracy, we applied these integrative data procession steps to a 2-channel dilution standard dataset
103 ¹⁵ and a 3-channel dataset ²² (**Figure 1 – Upper Right, see Methods**).

104 To facilitate downstream analysis of the pSILAC data, we herein also present an open-source R
105 package, *Kdegger*, which aims to streamline the processing of pulse SILAC DIA-MS data. *Kdegger*
106 performs data formatting, quality control, calculation of peptide and protein turnover (k_{loss}), degradation
107 rates (k_{deg}), comparative analysis, and visualization (**Figure 1, Lower Middle, see Methods**). The
108 package supports data from various raw data processing software, making it a versatile tool for diverse
109 proteomics workflows. Finally, we applied the entire workflow to a biological investigation on protein
110 turnover regulation in a cisplatin-resistant ovarian cancer model (A2780 and A2780Cis cell lines). By
111 integrating the multiplex-DIA data with other omics, we gained novel insights into the mechanisms
112 underlying drug resistance in this highly aneuploid cancer model (**Figure 1, Lower Right**).

113 **Improved Identification of Multiplex-DIA-MS Datasets Through Machine Learning-Guided** 114 **Dynamic Selection of Isotopic Labeling Features**

115 To assess the effectiveness of the LBL and compare it to the ISW, we analyzed the A2780 standard
116 2-channel SILAC dilution series (H:L: 1:16, 1:8, ..., to 8:1,16:1) as the first benchmarking dataset ¹⁵. We
117 found that, in a library-free analysis of a 1:1 sample, the LBL led to the identification of 142,363
118 precursors and 7,785 protein groups (**Figure 2A, Figure S1A**), which was 3.8% and 12% more than the
119 ISW result. Strikingly, this is 147.6% and 35.3% more precursors and protein groups than we reported
120 previously in the same samples analyzed using ISW and an extensive, project-specific hybrid library
121 (188,886 peptide precursors corresponding to 7,457 proteins) in Spectronaut v13 ¹⁵, demonstrating the
122 improved software performance especially the deep learning features included in recent DIA data analysis
123 software tools ¹⁹⁻²¹. Furthermore, in the dilution series of A2780, the LBL outperformed the ISW by

124 identifying more precursors and proteins across mixing conditions (**Figure 2B, Figure S1B**). In the light-
125 dominant samples, the LBL identified slightly more features (about 10% more precursors and 5% more
126 protein groups), but dramatically overperformed ISW in the heavy-dominant samples, as expected. The
127 LBL workflow successfully reached the dynamic assignment of the scoring weight to both channels
128 (**Figure 2C**).

129 As the second benchmarking dataset, we leveraged a public dataset of HeLa cells with 3 SILAC
130 labeling states (Light, Medium, and Heavy)²². This dataset consisted of two different compositions, i.e.,
131 **mix1** (light-dominant, H:M:L = 15:15:70) and **mix2** (medium&heavy-dominant, H:M:L = 40:40:20). In
132 both mixes, we found that the LBL identified more precursors and proteins, leading to a greater number
133 of pairwise ratios between the three channels (**Figure 2D, 2E, Figures S1C**). Similar to the 2-channel
134 result, LBL yielded a slight improvement in the light-dominant **mix1** (5.3% and 12.7% more precursors
135 and proteins, respectively), but a more dramatic improvement in **mix2** in which light peptides only account
136 for 20% (115.9% and 28.9% more precursors and proteins, respectively). The number of missing values
137 across the replicates was extremely low in the results based on the LBL workflow, especially at the protein
138 level (**Figure 2E**). The scoring weight histogram of this experiment further compellingly validated the
139 LBL algorithm (**Figure 2F**).

140 Next, to showcase the practical application of the LBL workflow in a real pSILAC experiment,
141 we analyzed the third dataset obtained from the A2780 cell line (the parental line). LBL consistently
142 identified 6,900 proteins on average, covering four time points and three experimental replicates (**Figure**
143 **2G**). Furthermore, to validate the general applicability of LBL, we analyzed a pSILAC experiment
144 performed in two fibroblast cell lines, for which we acquired the datasets using two independent LC-MS
145 platforms, Orbitrap Fusion Lumos and timsTOF Ultra (**Figure 2H, see Methods**). Impressively, with 2.5
146 times shortened gradient and less than 10% sample amount (130 ng vs 1.5 µg), using the timsTOF Ultra
147 platform we identified in total 227,242 precursors and 9,270 protein groups (30.1% and 31.2% more than
148 using Lumos, respectively, **Figure 2H**), and a consistent identification of 9,130 proteins on average
149 (**Figure 2I**). This analysis demonstrated the versatility and reliability of LBL across instruments from
150 different vendors and emphasized the evolving MS technology.

151 Together, we demonstrated the LBL workflow provides consistent improvement of peptide
152 detection using various multiplex DIA-MS datasets.

153 **Channel-specific Q-value filtering for quantifying ratios of isotopically labeled peptides.**

154 As outlined earlier, LBL performs the elution group scoring across all channels and individually
155 for each channel, leading to the estimation of the group and channel-specific Q-values. These values can
156 be used for quantitative data filtering by e.g., choosing one of the “Group Q-value”, the “Min Q-value”,
157 or the “Max Q-value” options in Spectronaut. In “Min Q-value”, only one of the channels needs to
158 independently pass the $Q < 0.01$, while in “Max Q-value”, all the channels present in the sample need to
159 pass $Q < 0.01$ as the most conservative filtering option. We evaluated these three new built-in options
160 using standard 2- and 3-channel SILAC datasets and in the pSILAC experiment of A2780 cells (**Figure**
161 **3**).

162 In the 2-channel dilution series, the “GroupQ” and “MinQ” provided a similar quantification result
163 with comparable numbers of quantified protein-level ratios and accuracy. As expected, the “MaxQ” led
164 to more conservative results filtering with a considerable data loss in the extreme ends of the dilution
165 series, which seemed to be overall intensity dependent (**Figure 3A, 3B**). As expected, MaxQ provided a
166 more stringent filtering that improved quantification precision, as shown by the significantly reduced
167 standard deviations in the H/L ratio distributions, while maintaining similar overall median
168 values. Interestingly, at the precursor level, there is a large overlap between the quantified precursors
169 between the “GroupQ” and “MinQ” filtered results (**Figure S1D**), while GroupQ even consistently
170 identified slightly more precursors (~3.3% on average), emphasizing the benefit of simultaneously
171 considering all channels.

172 The analysis of the 3-channel experiment yielded similar conclusions. While the median protein-
173 level ratio values remained relatively consistent across all three filtering options, the “MaxQ” filtering led
174 to an increased precision (**Figure 3C**). The application of “MaxQ” resulted in a significant reduction in
175 the number of quantified proteins (on average 29.9% in mix1 and 9% in mix2), including those with a CV
176 across replicates $< 20\%$ (on average 14.1% in mix1 and 5.4% in mix2), indicating the more conservative
177 filtering compromised by the partial loss of high-quality signals.

178 To benchmark these results against another multiplex DIA-MS workflow, we applied the
179 workflow recommended in plexDIA method with the matrix channel Q-value filtering ($Q < 0.01$) to
180 analyze both the 2- and 3-channel experiments (**Figure S2**). Notably, the results from plexDIA workflow
181 closely matched those of the “MaxQ” filtering with a higher number of quantified protein-level ratios in
182 “MaxQ” (up to 30% in the 1/16 and 16/1 H/L samples) but slightly better precision using plex-DIA

183 (Figure S2A). In the 3-channel sample, we observed a similar trend but a slightly better precision of
184 “MaxQ” (Figure S2C). When the analysis was restricted to the same precursors and proteins, the ratio
185 distributions appeared nearly identical (Figure S2B, S2D).

186 Lastly, in the Q-value filtering comparison performed using the real pSILAC A2780 samples, the
187 “MaxQ” filtering significantly reduced the number of quantified protein ratios in the first time point
188 (Figure 3E, 3F) and the reported values appeared to have an overall lower median. However, checking
189 the overlapping IDs, the distributions were also largely identical (Figure S1E), again suggesting the
190 “MaxQ” reduced noise data points for quantification while discarded sizeable proteins with a good across
191 replicate CV < 20% (32.7% and 13.8% on average in the 1st and 2nd-time point; Figure S3F).

192 In summary, in all datasets, both “Group Q-value” and “Min Q-value” options retain higher
193 sensitivity, while the “Max Q-value” is more stringent and delivers improved quantification precision,
194 with the cost of a considerable reduction in quantified proteins.

195 ***KdeggeR*: A Comprehensive R Package for Proteomic Turnover Analysis**

196 To streamline the analysis of pSILAC-DIA data, herein, we further present *KdeggeR*, an
197 integrative R package. *KdeggeR* offers functions for data import from multiple common raw data
198 processing tools, ensuring compatibility across platforms, followed by data cleaning and quality control
199 steps to prepare the data for analysis (Figure 4A). At the precursor level, *KdeggeR* allows for the
200 estimation of k_{loss} using three different methods, which can then be aggregated to the peptide or protein
201 level. This aggregation is performed by applying a weighted average of precursor-level k_{loss} values, with
202 weights determined by the precursor-level fit quality and the number of data points. *KdeggeR* also
203 calculates protein degradation rates (k_{deg}) and half-lives ($t_{1/2}$) using either user-provided or theoretically
204 estimated cell division rates (k_{cd}), allowing for flexible k_{deg} determination. Visualization tools within the
205 package enable users to assess precursor- and protein-level fitting results, as well as conduct comparative
206 turnover analyses between different conditions (see **Methods** for more details).

207 We utilized the *KdeggeR* package to investigate protein turnover regulation between the A2780
208 and A2780Cis ovarian cancer cell lines²³. A triplicate pSILAC experiment was performed with four time
209 points, i.e., 1, 4, 8, and 12 hours (Figure 1, Lower Right) and the raw data were processed using LBL.
210 Figure 4B demonstrates the precursor-level quality filtering in *KdeggeR*. We applied a series of filtering
211 criteria considering data completeness and assumptions specific for a pSILAC experiment (see **Methods**).

212 In addition, outlier values in the early time point (i.e., the first data point) can be removed by performing
213 a linear regression on the log-transformed H/L ratios ($\ln(H/L + 1)$) and conducting a statistical test to
214 determine if the first time point significantly deviated from the residual distribution ("Outlier filtering").
215 It has been established that the first short labeling time point can be critical for precisely determining the
216 turnover rates of short-lived proteins^{9,13} or modified peptides¹³. However, due to the lower intensity of
217 heavy-labeled peptides at this initial stage in many pSILAC experiments, the H/L ratios practically tend
218 to exhibit substantially higher noise compared to later time points, which may impact the accuracy of
219 turnover rate quantification. As shown in **Figure 4B**, applying this data filtering approach reduced the
220 standard deviations of H/L ratio distributions, particularly in the first and second time points, while
221 retaining significantly more values with the "GroupQ" filter compared to the more conservative "MaxQ"
222 filter. After fitting precursor-level data with a linear regression of the log-transformed ratios, the majority
223 of curves passed $R^2 > 0.9$ (**Figure S3A**). Finally, the precursor and protein-level rates of loss (k_{loss}) values
224 were estimated using the RIA method and a weighted average (see **Methods**). This resulted in the
225 estimation of 6866 protein k_{loss} values on average across the two cell lines and replicates (**Figure S3B**),
226 which were further transformed into k_{deg} for the downstream analysis. As an example, *KdeggeR* facilitated
227 the identification of MBNL1, a protein exhibiting significantly slower turnover in the A2780Cis (resistant)
228 cell line compared to the parental A2780 line (**Figures 4C-E, S3C**) as visualized by the plotting functions
229 provided within the *KdeggeR* package.

230 Together, *KdeggeR* allows for accurate and flexible calculation of protein turnover rates for users
231 without strong bioinformatic background.

232 **Multi-omics Analysis Reveals Proteomic Buffering via Protein Degradation in a Cisplatin-Resistant** 233 **Ovarian Cancer Model**

234 Cancer development is often linked to genomic instability and the adaptive evolution of malignant
235 clones. This results in potential genomic alterations conferring selective advantages, including varying
236 responses to chemotherapy. Previous studies, including our own, have demonstrated that cells can exploit
237 the protein degradation system to maintain proteostasis in the face of cell aneuploidy and genomic
238 imbalance^{10,12,24-26}. The A2780 and A2780Cis ovarian cancer cell lines represent a well-established model
239 for studying cisplatin resistance²³, with distinct karyotypic abnormalities in both parental and cisplatin-
240 resistant cells documented. These abnormalities have been characterized through genomic^{27,28} and

241 proteomic²⁹ analyses. However, a comprehensive exploration of protein turnover and its role in driving
242 drug resistance in this drug-resistance model has been lacking.

243 To investigate the role of protein turnover in regulating genomic imbalance-associated drug
244 resistance, we conducted an integrative multi-omics analysis of the aneuploid A2780 and A2780Cis cell
245 lines. By combining proteomic data—protein abundance and degradation rates (k_{deg})—with transcriptomic
246 data from a previous study²⁷, we firstly observed a positive correlation between mRNA and protein log₂
247 fold changes ($R = 0.661$, **Figure S4A**), suggesting a good match between two independent experiments
248 from different laboratories. Furthermore, the correlation between mRNA and k_{deg} was weakly positive (R
249 $= 0.145$, **Figure S4B**), in line with our previous work in HeLa cells^{10,11}, reinforcing the idea that mRNA-
250 k_{deg} correlation is a valuable indicator of posttranslational buffering by protein turnover. Next, we used
251 the copy number alteration information (CNA) from a published study²⁸ performed in the same cell lines
252 and mapped the protein-coding genes to the integrated dataset (**Figure 5A**). Reassuringly, the mRNA
253 levels largely followed the expected trend based on the CNA data, and the same trend was apparent in
254 protein abundance data, although the dosage change seemed to be mitigated (**Figure 5A**).

255 To explore posttranslational buffering in aneuploid cells, we focused on genes affected by CNA
256 and encoding protein complex subunits (Corum 4.0³⁰). In particular, we plotted the correlation between
257 mRNA and k_{deg} which could better inform the proteome buffering existence than protein~ k_{deg} correlations
258 as we showed previously¹⁰. Remarkably, proteins encoded by CNA-affected genes involved in complexes
259 exhibited a significantly stronger mRNA- k_{deg} correlation ($R = 0.537$, $P = 1.83 \times 10e^{-9}$, Fisher's z-test) than
260 CNA-affected proteins not participating in protein complexes ($R = -0.05$), providing compelling evidence
261 of large-scale protein complex buffering through protein turnover in this highly aneuploid system. These
262 findings therefore highlight the critical role of protein degradation in buffering against genomic instability,
263 particularly in maintaining the stoichiometry of protein complexes.

264 **Comprehensive Protein Turnover Analysis Reveals Mechanistic Insights into Cisplatin Resistance** 265 **in the A2780 Ovarian Cancer Model**

266 In addition to proteome buffering effect, to explore the functional role of protein turnover in the
267 drug-resistant phenotype, we conducted a statistical analysis to identify proteins with significantly altered
268 abundance and degradation rates in the A2780Cis cell line (**Figure S4D, S4E, Table S1**). We identified
269 1,961 proteins with significant changes in abundance and 1,356 proteins with significantly altered

270 degradation rates, with 407 proteins commonly regulated in both datasets (**Figure 6A**), suggesting both
271 protein abundance and protein turnover regulation are important parts of the drug-resistant phenotype in
272 A2780. Notably, proteins with significantly upregulated k_{deg} values overlapped more with the group of
273 significantly downregulated proteins ($N = 73$, Fisher's exact test $P = 7.11 \times 10^{-17}$) than upregulated ($N =$
274 22) (**Figure 6B**), demonstrating a generally coordinated correlation. To corroborate these proteins and
275 their functions, we performed an enrichment analysis using Metascape ³¹, which revealed a densely
276 interconnected cluster of proteins significantly enriched in pathways such as "ATP synthesis coupled
277 electron transport" ($P = 7.94 \times 10^{-30}$) and "Oxidative phosphorylation" ($P = 3.16 \times 10^{-31}$), primarily comprising
278 proteins with increased degradation rates and decreased abundance (**Figure 6D, Table S2**).

279 Next, we conducted a two-dimensional gene ontology biological process (GOBP) enrichment
280 analysis, comparing relative changes in both protein abundance and degradation rates between the
281 A2780Cis and A2780 cell lines (**Figure 6C, Table S3**). The correlation between median \log_2 fold changes
282 for significant GOBP terms was overall weakly negative ($R = -0.244$) as expected. Several processes, such
283 as "TCA cycle", "lipid homeostasis", "cell redox homeostasis" or "oxidation-reduction process," showed
284 increased abundance but reduced turnover, the latter align with mechanisms previously linked to cisplatin
285 resistance ^{32,33}. Conversely, proteins involved in "mitochondrial respiratory chain complex I" or
286 "translation" displayed decreased abundance and increased turnover, consistent with findings from the
287 Metascape analysis. Interestingly, terms related to proteasome-mediated protein degradation were
288 downregulated at both proteome and turnover levels.

289 Additionally, we utilized the DepMap portal ³⁴ to identify genes significantly associated with
290 cisplatin sensitivity by examining the correlation between transcript abundance and cisplatin response (N
291 $= 414$, $P < 0.01$). Notably, 107 of these genes were mapped to our proteomic datasets, and a substantial
292 number of proteins showed significant regulation, either at the protein abundance or degradation level
293 (**Figure 6E, Table S4**). Proteins that exhibited significant regulation at both levels, but with opposing
294 trends (i.e., coordinated regulation)—upregulation in one accompanied by downregulation in the other—
295 may represent key players involved in mediating drug resistance. Among these, NDUFB11, a
296 mitochondrial electron transport chain protein, was the only one displaying significantly increased
297 degradation (**Figure 6F**) alongside decreased abundance.

298 A detailed review of DepMap data indeed revealed a negative correlation between NDUFB11
299 transcript levels and cisplatin sensitivity among a total of 154 cell lines (**Figure 6G**), validating that its

300 reduced abundance, which may be driven by increased turnover, is associated with or contributes to
301 enhanced drug resistance in the A2780Cis cell line. Moreover, MBNL1 and OXSM, which showed
302 increased protein levels and reduced degradation rates in the resistant cells (**Figure S4H**), were positively
303 correlated with cisplatin resistance according to DepMap transcript profiles (**Figures S4F, S4G**),
304 reinforcing their potential roles in mediating the cisplatin resistant phenotype. In conclusion, these
305 findings highlight the strong relationship between protein turnover and cisplatin resistance, with key
306 proteins involved in mitochondrial function, redox homeostasis, and oxidative phosphorylation showing
307 significant regulation.

308 **Discussion**

309 Multiplex DIA-MS, when integrated with pSILAC⁵⁻⁸, enables precise quantification of protein
310 turnover across multiple time points under various biological conditions^{9-12,14,15,35-37}. This approach is
311 particularly well-suited for time-course experiments, allowing for reproducible profiling of large numbers
312 of peptides. Moreover, recent advances in library-free DIA-MS data analysis driven by machine and deep
313 learning¹⁹⁻²¹ have dramatically streamlined the process of DIA-MS data identification and quantification
314 by removing the necessity of generating extensive project-specific spectral libraries, making DIA-MS
315 workflows more efficient and scalable for complex proteomic studies.

316 The LBL in Spectronaut represents an advancement in multiplex DIA-MS data analysis,
317 particularly for experiments involving dynamic isotopic labeling such as pSILAC. Unlike earlier methods
318 that focus on a single channel for signal extraction, the LBL workflow takes a flexible approach by
319 integrating data across all labeling channels. During the peak picking and elution group scoring stages,
320 LBL considers both channel-specific and cross-channel metrics to extract more comprehensive and
321 reliable signals. Moreover, it takes full advantage of the label-free directDIA algorithm in Spectronaut²⁰,
322 effectively eliminating the need for creating a project-specific spectral library. Indeed, we demonstrated
323 that LBL outperformed the ISW in the analysis of multiple labeling datasets, identifying significantly
324 more precursors and protein groups across various conditions and sample compositions. Importantly, we
325 demonstrated improved identification in a standard experiment that included more than two labeling
326 channels, showcasing the potential of LBL to handle different labeling experiments, which theoretically
327 could extend to N channels. This is particularly promising as the interest in multiplexing DIA-MS
328 continues to grow, with new reagents being developed for MS quantification to leverage additional

329 channels in more intricate experimental designs or specialized workflows, such as single-cell proteomics
330 ^{17,38}. On the other hand, strategies like ISW or “Spike-in” (with a heavy sample as a reference) may remain
331 more suitable for experiments using spike-in standards ³⁹. Finally, we demonstrated that LBL can be
332 effectively utilized across two distinct mass spectrometry platforms—Orbitrap Fusion Lumos and
333 timsTOF Ultra. This adaptability suggests that LBL remains useful even as mass spectrometry
334 technologies evolve, with improvements in speed, resolution, and sensitivity.

335 Proper FDR control is critical in multiplex-DIA experiments because it ensures the reliability and
336 accuracy of the protein quantifications across multiple labeling channels. LBL leverages machine learning
337 to calculate both cross-channel scores and channel-specific scores. These enable channel-specific FDR
338 filtering of the quantification results through three Q-value filtering strategies, “GroupQ”, “MinQ”, and “MaxQ”.
339 Based on our evaluation, the “GroupQ” and “MinQ” (at least one channel $Q < 0.01$) options offered higher
340 sensitivity by retaining more quantification data, while “MaxQ” (all channels $Q < 0.01$) provided more
341 stringent filtering, improving precision at the cost of reduced sensitivity. This loss of data in the “MaxQ”
342 setting can be especially impactful in studies focused on low-abundance proteins or studies focusing on
343 peptide-level quantification ^{9,13,35}. Researchers may want to consider the choice of filtering strategy based
344 on their specific experimental needs. For studies that prioritize sensitivity, the “GroupQ” or “MinQ”
345 filtering options are more appropriate, while those aiming for the highest level of precision and confidence
346 in their quantification may benefit from using “MaxQ”, albeit with reduced overall data retention.
347 However, it is important to point out that “GroupQ” and “MinQ” results practically cover almost all
348 “MaxQ” results and that Spectronaut offers flexibility with these filtering options, allowing users to tailor
349 their analyses based on their specific experimental requirements. For example, experiments using a
350 booster sample channel might benefit from channel-specific Q-value filtering ¹⁸.

351 To provide a comprehensive workflow for the analysis of pSILAC data obtained through
352 multiplex-DIA-MS, we have developed the R package *KdeggeR*. A few other software tools have been
353 developed previously, among them *proturn* ³⁶, which offers a user-friendly Shiny app and was primarily
354 designed for pSILAC-TMT experiments; *JUMPt* ⁴⁰ calculates protein turnover rates using a differential
355 equation-based model to account for amino acid recycling, and is particularly useful in in vivo studies
356 such as mouse models; *SPLAT* enables a more specialized workflow for simultaneous protein localization
357 and turnover analysis (<https://lau-lab.github.io/splat/>); or *turnoveR*, which was designed to work
358 with SVM files and Massacre output (<https://github.com/KopfLab/turnoveR>). While some of these

359 existing packages can estimate protein degradation rates from pSILAC-DIA data, they sometimes require
360 the user to perform manual data pre-processing. *KdeggeR* thus offers an alternative and a more
361 streamlined workflow by handling data import, peptide-to-protein processing, and various data
362 visualization functions within a single package. However, a limitation of the current version of *KdeggeR*
363 is its inability to account for amino acid recycling, which can be critical in-vivo systems and is already
364 provided by other software tools such as *JUMPt* ⁴⁰.

365 Finally, we applied the complete workflow to study the potential contribution of protein turnover
366 in the regulation of drug resistance in the A2780 ovarian cancer cell line model ⁴¹. The cisplatin-resistant
367 cell line A2780Cis was developed by chronic exposure of the parent cisplatin-sensitive cell line A2780 to
368 increasing concentrations of cisplatin, and the development of the drug-resistant phenotype was associated
369 with marked cytogenetic changes ⁴¹. In this study, we leveraged an integrative multi-omics approach to
370 uncover the mechanisms through which protein degradation helps buffer against genomic imbalances
371 associated with cisplatin resistance. Our focus on genes affected by copy number alterations (CNA)
372 provided compelling evidence of large-scale protein complex buffering ²⁴ through protein degradation as
373 observed before ¹². We observed that proteins encoded by CNA-affected genes involved in complexes
374 exhibited a much stronger mRNA- k_{deg} correlation compared to those not involved in complexes,
375 underscoring the importance of turnover dynamics in maintaining the stoichiometry of protein complexes
376 under stress conditions like genomic instability.

377 In terms of cisplatin resistance, our analysis of the A2780Cis cell line revealed significant changes
378 in both protein abundance and degradation rates. Proteins with upregulated k_{deg} values tended to have
379 reduced abundance, indicating that specific degradation mechanisms potentially critical for maintaining
380 drug resistance. Notably, key pathways such as oxidative phosphorylation and ATP synthesis were
381 significantly enriched among proteins with increased degradation rates and reduced abundance,
382 suggesting that mitochondrial function might be an important factor in the cisplatin resistance phenotype.
383 Moreover, processes such as cell redox homeostasis, and the TCA cycle were associated with increased
384 abundance and decreased turnover. Conversely, pathways related to mitochondrial respiratory chain
385 complex I and translation showed decreased abundance and increased turnover, highlighting a potential
386 disruption in energy metabolism and protein synthesis machinery in the resistant cells. Several studies
387 have highlighted the potential role of alterations in drug uptake, enhanced DNA repair pathways such as
388 nucleotide excision repair (NER), and cytosolic drug inactivation as the main contributing factors to

389 cisplatin resistance^{23,42}. Other studies have suggested that drug inactivation in the cytosol by the cell
390 redox system involving metallothionein³² and/or glutathione³³ may contribute to cisplatin resistance.
391 This aligns with our observation of an enhanced cellular redox system in the cisplatin-resistant A2780Cis
392 cell line.

393 Finally, we used the DepMap portal³⁴ to identify genes associated with cisplatin sensitivity,
394 revealing several proteins with significant regulation at both the protein abundance and degradation levels.
395 Of particular interest was **NDUFB11**, a mitochondrial electron transport chain protein, which exhibited
396 increased degradation and decreased abundance. This suggests that altered turnover of mitochondrial
397 proteins and alterations in mitochondrial functions may contribute to drug resistance.
398 Similarly, **MBNL1** and **OXSM**, which showed increased protein levels and reduced degradation rates,
399 may represent important contributors to the cisplatin-resistant phenotype. The observed synergetic
400 mechanisms, such as increased protein degradation paired with reduced abundance, underscore the critical
401 role of turnover dynamics in maintaining cellular proteostasis under aneuploidy and drug stress.

402 In conclusion, our integration of multiplex DIA-MS with pSILAC and the development of the LBL
403 workflow in Spectronaut significantly enhance protein turnover quantification across multiple channels.
404 These advancements streamline complex proteomic studies and provide valuable insights into
405 mechanisms such as cisplatin resistance.

406 **Figure legend**

407 **Figure 1: A robust workflow for multiplex-DIA MS data analysis.** *Upper left:* Protein turnover
408 analysis on a large scale using dynamic stable isotope labeling by amino acids in cell culture (pSILAC),
409 combined with highly robust and reproducible multiplex data-independent acquisition (DIA) mass
410 spectrometry (MS), enables the quantification of thousands of protein turnover rates and facilitates
411 quantitative comparisons between multiple conditions. Datasets from two MS platforms (Orbitrap Fusion
412 Lumos and timsTOF Ultra) were processed. *Lower left:* In the previously reported inverted spike-in
413 workflow (ISW), peak picking and scoring relied solely on the light channel. In the labeled (“LBL”)
414 workflow, XIC peak picking, elution group scoring, and “Group Qvalue” calculation are performed across
415 all channels ($n = 2, 3, \dots, n$) in a combined fashion, facilitated by improved machine learning. *Upper*
416 *middle:* In addition to the Group Qvalue, our Spectronaut v19 (SN19) solution now offers channel-specific
417 Qvalue filtering options for more stringent quantification data filtering. In the “Min Qvalue” option, at

418 least one channel needs to be independently identified (Q value < 0.01), while in the “Max Qvalue” option,
419 all channels must be independently identified to accept the entire elution group. **Lower middle:** As part of
420 the workflow, we provide an R package named *KdeggeR* for the analysis of pulse SILAC DIA-MS data
421 from various raw data processing software, including data formatting, data filtering and QC, the
422 calculation of precursor-, peptide-, and protein-level protein turnover rates (Kloss), subsequent protein
423 degradation rate (k_{deg}) transformation, comparative data analysis, and data visualization. **Upper right:** We
424 evaluated the multichannel analysis implemented (e.g., in Spectronaut v19) using 2-channel standard
425 dilution samples and 3-channel standard datasets. Both datasets were acquired previously and are publicly
426 available (Salovska et al., 2021; Bortecen et al., 2024). **Lower right:** We demonstrated the feasibility of
427 the entire workflow by applying it to the study of protein turnover regulation in a cisplatin resistance
428 model of the highly aneuploid ovarian cancer A2780 and integrated the data with other omic layers. This
429 application highlighted the importance of studying protein turnover to derive biological insights into
430 complex phenomena such as the cancer drug resistance phenotype.

431 **Figure 2: Improved identification of multiplex DIA-MS datasets using machine learning to**
432 **dynamically select isotopic labeling features. (A)** Improved identification using the Labeled workflow
433 implemented in SN19 in the H/L = 1 sample of A2780; the numbers of identified IDs at the precursor
434 (left) and protein (right) levels are shown. **(B)** The Labeled workflow outperformed the inverted spike-in
435 workflow in the A2780 dilution series analysis; the numbers of identified IDs at the precursor and protein
436 (in brackets) levels are shown. **(C)** Scoring weight histogram from the 2-channel A2780 dilution series
437 experiment. **(D-E)** Number of precursors **(D)** and proteins **(E)** identified in the 3-channel HeLa standard
438 sample experiment; the numbers of IDs identified in an experimental replicate are shown. **(F)** Scoring
439 weight histogram from the 3-channel HeLa standard sample experiment. The bars represent the averaged
440 weights per condition/mix. **(G)** Protein-level identification in the pulse SILAC experiment in the A2780
441 cell line. **(H)** Precursor- and protein-level comparison of identifications between samples measured using
442 the timsTOF Ultra and Orbitrap Fusion Lumos platforms. **(I)** Protein-level identification in a pSILAC
443 experiment.

444 **Figure 3: The channel-specific Qvalue filtering for quantifying ratios of isotopically labeled**
445 **peptides. (A)** Comparison of protein-level ratio distribution in the A2780 standard dilution samples after
446 different Qvalue quantification filtering for multichannel samples (enabled in SN19); the dashed lines and

447 numbers represent the medians of the data distributions, shown using density plots; the points represent
448 individual values. **(B)** The histograms indicate the number of valid protein-level H/L ratios quantified in
449 the samples depicted in A. **(C)** Comparison of protein-level ratio distribution in the HeLa 3-channel
450 standard sample after different Qvalue quantification filtering. Ratios were calculated between channels
451 as indicated. The dashed lines indicate expected ratios based on sample composition; the numbers
452 represent observed median values. **(D)** Binned protein-level ratio CV based on 3 replicates in the HeLa
453 sample after different Qvalue quantification filtering. **(E)** Comparison of protein-level H/L ratios in the
454 pulse SILAC A2780 samples after different Qvalue quantification filtering. The numbers represent
455 observed median values. **(F)** Binned protein-level ratio CV based on 3 replicates in the A2780 pulse
456 SILAC sample after different Qvalue quantification filtering. groupQ, minQ, and maxQ refer to Group
457 Qvalue, Min Qvalue, and Max Qvalue filtering, which are the quantification settings in the data analysis
458 in SN19.

459 **Figure 4: KdeggeR, a comprehensive and integrative R package for proteomic turnover**
460 **analysis.** **(A)** The *KdeggeR* package streamlines pSILAC data analysis by providing functions for
461 importing data from multiple common raw data processing software tools, data cleaning, and quality
462 control. Next, precursor-level k_{loss} can be estimated by three different methods, and protein- and peptide-
463 level k_{loss} can be estimated by performing a weighted average of the corresponding precursor-level k_{loss}
464 values, considering precursor-level fit quality and/or the number of datapoints. Protein degradation rates
465 (k_{deg}) and half-life ($t_{1/2}$) are further calculated using cell division rate (k_{cd}) values provided by the user or
466 by using a theoretical k_{cd} value estimated from the k_{loss} value distribution. Visualization functions enable
467 inspection of the precursor- and protein-level fitting results and comparative analysis between multiple
468 conditions. **(B)** Demonstration of precursor-level quality filtering in the dynamic SILAC experiment
469 performed in the A2780 cell line. Data were analyzed using the LBL workflow and exported using the
470 Group, Min, and Max Qvalue channel quantification filtering. **(C-E)** An example of MBNL1, a protein
471 with a significantly slower turnover rate in the A2780Cis (resistant) cell line compared to the parental
472 A2780 cell line. **(C)** Protein-level k_{loss} fit to all precursor-level data. **(D)** Distribution of precursor-level
473 k_{loss} values corresponding to the MBNL1 protein. **(E)** A representative example of precursor-level k_{loss}
474 calculation by performing nonlinear least squares (nls) fitting using the relative isotope abundance (RIA)
475 of the light peptide. The plots were visualized using the KdeggeR package.

476 **Figure 5: Multi-omic analysis of the cisplatin-resistant model demonstrating proteomic buffering**
477 **through protein degradation. (A)** Copy number alterations (CNA) in the A2780 paired cell line model
478 (Parental A2780 vs. A2780Cis) were mapped to transcriptomic data, protein-level abundance data, and
479 protein degradation rate (k_{deg}) values measured by DIA-MS. The CNA and transcriptomic data were
480 generated by previous studies analyzing the same cell lines (Prasad et al., 2008; Behrman et al., 2021).
481 Relative differences between A2780Cis (resistant) and A2780 (parental) are shown on the y-axis, while
482 the x-axis depicts genes ordered by their chromosome location. Chromosomal regions with CNA are
483 highlighted in red. **(B)** Post-translational buffering through protein turnover of protein complex subunits
484 (Corum 4.0) encoded by genes with reported copy number alterations between the A2780Cis (resistant)
485 and A2780 (parental) cell lines, revealed by mRNA and k_{deg} fold change correlations. Statistical analysis
486 was performed using a z-test. Pearson correlation coefficients (R) and the number of proteins (N) are
487 shown. The dark red line represents a linear fit to the data with confidence intervals (pink).

488 **Figure 6: Protein turnover measurement provides biological insights into the drug resistance**
489 **phenotype in the A2780 cell line model. (A)** The number of statistically significant protein IDs identified
490 at the protein abundance and degradation levels (Benjamini-Hochberg FDR < 0.05 and absolute fold
491 change of at least 1.5). A moderated t-test was used for statistical analysis. **(B)** The number of significantly
492 up- and down-regulated proteins at the protein abundance and degradation (k_{deg}) levels, and their
493 overlapping protein identities. The circos plot was generated using Metascape. **(C)** A two-dimensional
494 plot depicts the results of the 2D enrichment analysis of gene ontology biological process (GOBP)
495 functional annotations. Protein abundance and degradation-level relative fold changes between A2780Cis
496 (resistant) and A2780 (parental) cell lines were used for enrichment analysis performed in Perseus. The
497 top 25 GOBP terms based on significance (enrichment P < 0.01 and number of proteins > 9) are shown.
498 The size of the circles represents the number of proteins, while the color represents the -Log₁₀ transformed
499 P value. **(D)** A protein cluster identified by the MCODE algorithm in the protein-protein interaction (PPI)
500 analysis performed using significantly regulated protein IDs (as depicted in B). Node colors represent the
501 respective up- or down-regulation at the protein abundance and degradation levels. **(E)** Genes associated
502 with sensitivity to cisplatin were identified using a custom correlation analysis in the DepMap portal and
503 mapped to the protein abundance and degradation data. The colors represent the respective up- or down-
504 regulation at the protein and protein turnover levels. Proteins with significant regulation at both levels and

505 with opposite trends are shown. **(F)** Precursor-level H/L ratio scatter plots of the NDUFB11 protein in
506 A2780 (left) and A2780Cis (right) cell lines; “a” indicates the slope of the line fitted using a linear fit to
507 the precursor-level data, which can be used as an estimate of the protein-level ratio. **(G)** The negative
508 correlation of NDUFB11 gene expression at the mRNA level with cisplatin IC₅₀ based on the GDSC1
509 dataset indicates that decreased NDUFB11 expression is significantly associated with increased IC₅₀
510 (resistance).

511 **Acknowledgement**

512 Y.L. thanks the support from the National Institute of General Medical Sciences (NIGMS),
513 National Institutes of Health (NIH) through Grant R01GM137031 to Y.L. We would like to thank Diego
514 Assis and Matthew Willets from Bruker Life Sciences, Billerica, MA for performing the LC-MS analysis
515 using the timsTOF Ultra platform.

516 **Author Contributions**

517 B.S. analyzed the MS data, performed the bioinformatics analysis, and prepared most illustrations
518 for the figures. W.L. prepared all the samples and performed MS measurements. O.B., T.G, and L.R.
519 contributed to the software development facilitating multiplex DIA-MS data analysis. P.L.G. and B.S.
520 developed the KdeggeR package. Y.L. secured funding and supervised the study. B.S. wrote the first
521 version of manuscript. All authors contributed to the writing of the manuscript.

522 **Methods**

523 **Key resources table**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Biological Samples		
A2780	Sigma	Cat #: 93112519
A2780Cis	Sigma	Cat #: 93112517
Fibroblast from Skin (#54)	Coriell Institute	
Fibroblast from Skin (#55)	Coriell Institute	
Chemicals and Reagents		

MEM, NEAA, no glutamine	Gibco (Thermo Fisher Scientific)	Cat #: 10370088
MEM for SILAC	Thermo Scientific	Cat #: PI88368
RPMI 1640 medium	Gibco (Thermo Fisher Scientific)	Cat #: 11875093
RPMI 1640 Medium for SILAC	Gibco (Thermo Fisher Scientific)	Cat #: 88365
Fetal bovine serum	Gibco (Thermo Fisher Scientific)	Cat #: A5256701
Fetal bovine serum (dialyzed)	Gibco (Thermo Fisher Scientific)	Cat #: 26400044
GlutaMAX™ Supplement	Gibco (Thermo Fisher Scientific)	Cat #: 35050061
HyClone Penicillin-Streptomycin	Cytiva	Cat #: SV30010
PBS, pH 7.4	Gibco (Thermo Fisher Scientific)	Cat #: 10010023
Trypsin-EDTA (0.25%), phenol red	Gibco (Thermo Fisher Scientific)	Cat #: 25200056
Heavy L-Arginine-HCl (13C6, 15N4, purity >98%)	Cortecnet	Cat #: CCN250P1
Heavy Lysine-2HCl (13C6, 15N2, purity >98%)	Cortecnet	Cat #: CCN1800P1
L-Proline	Sigma	Cat #: P0380
Urea	Sigma	Cat #: U5378
Halt™ phosphatase inhibitor	Thermo Scientific	Cat #: 78428
cOmplete™ protease inhibitor cocktail	Roche	Cat #: 11697498001
Ammonium bicarbonate	Sigma	Cat #: A6141
Bio-Rad protein assay kit	Bio-Rad	Cat #: 5000002
Sequencing-grade modified trypsin	Promega	Cat #: V5113
Formic acid	Thermo Scientific	Cat #: 85178
Trifluoroacetic acid, LC-MS grade	Thermo Scientific	Cat #: 85183
DTT	Sigma	Cat #: D0632
IAA	Sigma	Cat #: I1149
96-Well Macro SpinColumn	Harvard Apparatus	Cat #: 74-5657
96-Well Spin Column	The Nest Group, Inc	Cat #: 8003476378
ReproSil-Pur,120A, C18-AQ,1.9 um resin	Dr. Maisch	Cat #: r119.aq
PicoFrit LC-MS column	New Objective	Cat #: PF360-75-10-N-5
Cisplatin	Sigma	Cat #: C2210000
Cell Lifter, Fixed 2.0cm Blade	RPI	Cat #: 162424
2 ml eppendorf tube	Eppendorf	Cat #: 022363433
Corning® 100 mm TC-treated Culture Dish	Corning	Cat #: 430167
Cytoone 6-well Plate with Lid, TC-treated	USA Scientific	Cat #: CC7682-7506
Acetone	Fisher Scientific	Cat #: A18P4

LC-MS grade Acetonitrile	Thermo Scientific	Cat #: 85188
Water, Optima™ LC/MS Grade, Fisher Chemical™	Fisher Scientific	Cat #: W64
Methanol	Fisher Scientific	Cat #: A412P4
0.1% Formic Acid (v/v) in Water, LC-MS Grade	Fisher Scientific	Cat #: PI85171
Acetonitrile with 0.1% Formic Acid (v/v), Optima™ LC/MS Grade	Fisher Scientific	Cat #: LS120500
Ethyl alcohol, Pure	Sigma	Cat #: E7023
Equipment		
VialTweeter sonicator	Hielscher-Ultrasound Technology	Cat #: UP 2000St
SpeedVac	Thermo Scientific	
Nanodrop	Thermo Scientific	
Microplate Reader	BioTek	
ThermoMixer	Thermo Scientific	Cat #: 5382000023
Instruments		
Column heater controller	Sonation GmbH, Biberach	Cat #: PRSO-V1
Easy nLC 1200 system	Thermo Scientific	Cat #: 1200
Orbitrap Tribrid Lumos Mass Spectrometer	Thermo Scientific	
Deposited Data		
A2780 standard dilution sample set	PXD021922	
Fibroblast pSILAC sample set	x	
A2780 cells, parental and cisplatin-resistant, pSILAC and total proteome	x	
Software and Algorithms		
Spectronaut™ Professional+	v19	Biognosys AG
DIA-NN	v1.9	Demichev et al (2020), Derks et al (2023)
Perseus	v1.6.14.0	Tyanova et al (2016)
Rstudio	v4.3.1	R core team (2024)

524 **Sample sets**

525 *A2780 standard dilution sample set (2-channel SILAC)*. This sample set was measured in our previous
526 study¹⁵. Ovarian cancer cell line A2780 was cultured for at least eight passages in media containing

527 $^{13}\text{C}_6^{15}\text{N}_4\text{-Arg}$ and $^{13}\text{C}_6^{15}\text{N}_2\text{-Lys}$ to reach >99% labeling efficiency (as evaluated by MS) ¹⁵. The sample set
528 included the following H/L dilutions: 1:16, 1:8, 1:4, 1:2, 1:1, 2:1, 4:1, 8:1, and 16:1. The detailed sample
529 preparation and LC-DIA-MS protocol can be accessed in the original protocol and the raw files provided
530 at ProteomeXchange (**PXD021922**). In brief, a 4-hour method consisted of an MS1 survey and 33 MS2
531 scans of variable windows ⁹ on an Orbitrap Fusion Lumos Tribrid mass spectrometer (Thermo Scientific).
532 ***HeLa standard dilution sample set (3-channel SILAC)***. This sample set included data from a published
533 study ²² and was downloaded from ProteomeXchange (**PXD039578**). The cells were grown in high
534 glucose DMEM, dialyzed fetal bovine serum (Gibco), and heavy- ($^{13}\text{C}_6^{15}\text{N}_4\text{-Arg}$, $^{13}\text{C}_6^{15}\text{N}_2\text{-Lys}$),
535 intermediate ($^{13}\text{C}_6\text{-Arg}$, $\text{D}_4\text{-Lys}$) or light isotope-containing Lysine, Arginine for 10 days. The H:M:L
536 composition of the mix 1 sample was made to be 15:15:70, and the composition of the mix 2 sample was
537 40:40:20. These samples were analyzed in triplicates using the LC-DIA-MS as described in the original
538 paper (MS2-optimized; see ²² for details). In brief, a 105-min method consisted of an MS1 survey and 26
539 MS2 scans of equally sized windows of 23.3 m/z on a QExactive HF mass spectrometer (Thermo Fischer
540 Scientific).
541 ***Fibroblast pSILAC sample set (2-channel pulse SILAC)***. The skin fibroblast cell lines were purchased
542 from the Coriell Institute for Medical Research. The two cell lines are referred as cell line #54 and cell
543 line #55 in the current manuscript, respectively. The cells were cultured at 37 °C, and humidified 5% CO₂
544 in complete MEM medium supplemented with L-glutamine, 15% fetal bovine serum, and penicillin-
545 streptomycin. Cells were seeded on 6-well dishes in a complete growth medium at a density of 15,000
546 cells per cm², and after 24 hours, the cells were washed and subjected to pulse SILAC labeling for 1, 4, 8,
547 12, and 24 hours. The SILAC MEM medium was supplemented with 15% of dialyzed FBS, penicillin-
548 streptomycin, L-proline (200 mg/L), and $^{13}\text{C}_6^{15}\text{N}_4\text{-Arg}$ and $^{13}\text{C}_6^{15}\text{N}_2\text{-Lys}$. The dishes were washed with
549 PBS, snap-frozen in liquid nitrogen, and the cells were scraped into 100 μL of cell lysis buffer containing
550 10 M urea/ 100 mM ammonium bicarbonate, cOmplete™ protease inhibitor cocktail and the Halt
551 phosphatase inhibitors. The collected samples were snap-frozen and stored at -80 °C before further
552 processing.
553 ***A2780 cells, parental and cisplatin-resistant (2-channel pulse SILAC)***. The A2780 (parental cell line)
554 and A2780Cis (cisplatin-resistant cell line) were cultured in the RPMI media supplemented with 2 mM
555 glutamine, 10% FBS, and penicillin-streptomycin. Additionally, the A2780Cis cell line was cultured in
556 the presence of 1 μM cisplatin. After switching to SILAC heavy medium ($^{13}\text{C}_6^{15}\text{N}_4\text{-Arg}$ and $^{13}\text{C}_6^{15}\text{N}_2\text{-$

557 Lys), both cell lines were harvested in a triplicate experiment at 1, 4, 8, and 12 hours of labeling.
558 Additionally, a triplicate sample was harvested at time point 0 to analyze the total proteomes. The dishes
559 were washed with PBS, snap-frozen in liquid nitrogen, and the cells were scraped into 200 μ L of cell lysis
560 buffer containing 10 M urea/ 100 mM ammonium bicarbonate, cOmplete™ protease inhibitor cocktail
561 and the Halt phosphatase inhibitors. The collected samples were snap-frozen and stored at -80 °C before
562 further processing.

563 **Protein extraction and digestion**

564 Cell pellets in lysis buffer were thawed and sonicated at 4°C for 1 minute twice using a
565 VialTweeter device (Hielscher-Ultrasound Technology)¹¹. Afterward, the samples were centrifuged at
566 20,000 \times g for 1 hour to separate insoluble materials. Protein concentrations in the resulting supernatant
567 were measured using the Bio-Rad protein assay. Each protein sample was diluted to a final concentration
568 of 2 μ g/ μ L, reduced with 10 mM DTT at 56°C for 1 hour, and alkylated with 20 mM IAA in the dark at
569 room temperature for 1 hour. Reduced and alkylated proteins underwent precipitation-based digestion⁴³
570 or in-solution digestion. For the precipitation-based digestions (all A2780 samples), five volumes of a
571 cold precipitation solution (50% acetone, 50% ethanol, and 0.1% acetic acid) were added to the protein
572 mixture, and the samples were stored at -20°C overnight. The precipitated proteins were collected by
573 centrifugation at 20,000 \times g for 40 minutes, washed with cold 100% acetone, and centrifuged again under
574 the same conditions. Following acetone removal, residual acetone was evaporated in a SpeedVac. The
575 proteins were then digested overnight at 37°C with sequencing-grade porcine trypsin at a 1:20 enzyme-
576 to-substrate ratio in 300 μ L of 100 mM ammonium bicarbonate. For the in-solution digestion (fibroblast
577 samples), the samples were diluted five times with 100 mM ammonium bicarbonate prior to the addition
578 of trypsin in 1:20 enzyme-to-substrate ratio. The peptide mixture was acidified with formic acid and
579 desalted using C18 columns (MarocoSpin Columns, NEST Group INC.) according to the manufacturer's
580 instructions. The final peptide yield was quantified using a Nanodrop (Thermo Scientific).

581 **Mass Spectrometry Measurements**

582 ***Orbitrap Fusion Lumos platform.*** For LC-MS analysis, 1.5 μ g of the peptide mixture was analyzed as
583 previously described^{11,44}. Peptide separation was carried out using an EASY-nLC 1200 system (Thermo
584 Scientific) with a self-packed PicoFrit column (New Objective, Woburn, MA, USA; 75 μ m \times 50 cm)
585 containing ReproSil-Pur 120A C18-Q 1.9 μ m resin (Dr. Maisch GmbH, Ammerbuch, Germany). Peptides

586 were eluted over a 150-minute gradient using buffer B (80% acetonitrile, 0.1% formic acid) from 5% to
587 37%, with buffer A (0.1% formic acid in water) as the corresponding solvent. The flow rate was set to 300
588 nl/min, and the column was maintained at 60°C using a column oven (PRSO-V1; Sonation GmbH,
589 Biberach, Germany). The separated peptides were analyzed on an Orbitrap Fusion Lumos Tribrid mass
590 spectrometer (Thermo Scientific) equipped with a NanoFlex ion source, with a spray voltage of 2000 V
591 and a capillary temperature of 275°C. The DIA-MS method included an MS1 survey scan followed by 33
592 MS2 scans with variable windows, as described previously^{20,45}. The MS1 scan range was 350–1650 m/z
593 with a resolution of 120,000 at m/z 200. The MS1 AGC target was set to 2.0E6, with a maximum injection
594 time of 100 ms. For MS2, the resolution was set to 30,000 at m/z 200, with a normalized HCD collision
595 energy of 28%. The MS2 AGC target was 1.5E6, and the maximum injection time was 50 ms. The default
596 peptide charge state was set to 2. Both MS1 and MS2 spectra were recorded in profile mode.

597 ***timsTOF Ultra platform (fibroblast pSILAC dataset)***. Peptides (130 ng) were separated within 52-minute
598 ACN gradients on a 25cm x 75µm column (Ion Opticks) using a nanoElute2 LC. The LC system was
599 connected via a CaptiveSpray Ultra source to trapped ion mobility – quadrupole time-of-flight MS
600 (*timsTOF Ultra*, Bruker Daltonik). The MS was operated in dia-PASEF mode⁴⁶ with 3 PASEF mobility
601 scans, each with 20 DIA variable windows (a “20 × 3” method; Bruker Daltonics)⁴⁷.

602 **Raw data processing**

603 ***Label-free DIA-MS data analysis (A2780 and A2780Cis)***. The label-free data analysis was performed in
604 Spectronaut v19 using directDIA+ against a human SwissProt sequence database (N = 20,399 entries,
605 downloaded in September 2022) using the default settings²⁰. Briefly, the Trypsin/P was used as a cleavage
606 rule with up to 2 missed cleavages; “Carbamidomethyl(C)” was set as a fixed modification, and
607 “Acetyl (Protein N-term)” and “Oxidation(M)” were set as variable modifications; Top3-6 Best N
608 Fragments per peptide were enabled. The precursor Q-value and the experiment-wide protein Q-value
609 were set to 0.01, and the run-wise protein Q-value was set to 0.05. The quantification was performed on
610 the MS2 level, and the cross-run normalization was enabled. The peptide and protein quantification were
611 performed using max Top 3 precursors and Top 3 stripped peptide sequences, respectively. The
612 “Minimum Log2 Precursor Quantity” was set to 3.

613 ***Multiplex DIA data analysis using the “Labeled workflow” (LBL)***. The multiplex DIA data analysis was
614 performed in Spectronaut v19 using the library-free “Labeled” workflow. The analysis was performed

615 using directDIA+ against a human SwissProt sequence database (N = 20,399 entries, downloaded in
616 September 2022) using the default settings with modifications as described below. The search parameters
617 were the same in all datasets across MS platforms.

618 In the Pulsar Search: the Trypsin/P was used as a cleavage rule with up to 2 missed cleavages; the
619 labeling was set to two channels with no labels specified in Channel 1 and “Arg10” and “Lys8” specified
620 in Channel 2; “Carbamidomethyl(C)” was set as a fixed modification, and “Acetyl(Protein N-term)” and
621 “Oxidation(M)” were set as variable modifications; in the Workflow tab, the “In-Silico Generate Missing
622 Channels” option was enabled with “label” as a Workflow; in the Result Filters tab, Top3-6 Best N
623 Fragments per Peptide were used, and the “Overlapping between Channels” was enabled to exclude
624 fragments shared between channels for the accurate estimation of channel-specific FDR.

625 In the DIA Analysis: in the Identification tab, the precursor Q-value and the experiment-wide
626 protein Q-value were set to 0.01, the run-wise protein Q-value was set to 0.05; in the Quantification tab,
627 the Multi-Channel Q-value filter was either set to “Group Q-value”, “Max Q-value”, or “Min Q-value” to
628 evaluate channel-specific Q-value filtering options. The quantification was performed on MS2 level, and
629 the cross-run normalization was enabled. The “Exclude All Multi-Channel Interferences” option was
630 enabled. The peptide and protein quantification were performed using max Top 3 precursors and Top 3
631 stripped peptide sequences, respectively. The “Minimum Log2 Precursor Quantity” was set to 3. In the
632 Workflow tab, the “Multi-Channel Workflow Definition” was set to “Labeled”.

633 ***Multiplex DIA data analysis using the “Inverted Spike-In” workflow (ISW).*** For the “Inverted Spike-In
634 analysis, the “Multi-Channel Workflow Definition” was set to “Spike-In” and both “Inverted” and
635 “Reference-based Identification” were enabled in Spectronaut v19. Other parameters were kept as
636 described in the section above.

637 ***Multi-Channel Experiment Processing and Scoring in Spectronaut.*** Spectronaut organizes all channels
638 corresponding to a given peptide into “ElutionGroups,” representing a group of peptide precursors
639 expected to elute simultaneously. Extracted ion chromatograms (XICs) are obtained for each group from
640 the relevant MS2 scans. The peak-picking strategy depends on the specific multi-channel processing mode
641 selected. By default, Spectronaut utilizes the “Labeled” workflow for multi-channel ElutionGroups, in
642 which XIC peak picking is performed across all channels in a combined fashion. Each peak is assigned
643 scores based on both channel-specific and cross-channel features, for both MS1 and MS2 data.

644 The final score per ElutionGroup is determined during the machine learning step, with the strategy
645 being workflow dependent. In the "Labelled" (LBL) workflow, all channels, along with their specific and
646 cross-channel scores, are considered collectively in the machine learning process, allowing for dynamic
647 adaptation to systematic changes in channel ratios which are common in pSILAC experiments. These
648 scores are then used to compute the "Group Q-value" for each ElutionGroup. Additionally, channels are
649 scored independently based on channel-specific metrics, which are used to determine channel-specific Q-
650 values.

651 Note, since this filtering is performed at the precursor level, the quantification of an elution group
652 (and thus the ratios between the channels) will be identical for those precursors passing the FDR filtering
653 by multiple options.

654 **Spectronaut results export and report processing**

655 *Label-free DIA-MS data (A2780 and A2780Cis).* For the total proteome analysis, the data were exported
656 using the protein pivot report using PG.ProteinGroups as a unique protein id and the PG.Quantity as a
657 quantification column.

658 *Multiplex DIA-MS data.* The precursor/elution group (EG) level pivot report was exported from
659 Spectronaut v19. The "EG.Channel1" and "EG.Channel2" (for a 2-channel experiment), and
660 "EG.Channel3" (for a 3-channel experiment) quantities were used as quantification values, and the
661 "EG.PrecursorId" column as the unique precursor id column. For protein-level quantification of the
662 multiplex DIA-MS data, the precursor-level ratios were estimated first as the ratios between the channels,
663 and then the protein-level ratios were calculated as a median value of all precursor-level ratios
664 corresponding to a unique protein id ("PG.ProteinGroups"). In all replicate experiments (HeLa 3-channel,
665 A2780 pSILAC), the replicates were aggregated to obtain an average ratio by calculating a mean and CV
666 of non-transformed ratio values after filtering for precursor values quantified in all 3 replicates.

667 **Multiplex DIA-MS data analysis in DIA-NN.**

668 To benchmark the multiplex DIA-MS analysis in Spectronaut, we also analyzed the data using
669 DIA-NN (version 1.9)¹⁹ using the plexDIA recommended workflow¹⁷ and largely followed the
670 parameters used previously to analyze the 3-channel HeLa standard sample experiment²². A predicted
671 spectral library was generated using the default settings from the same FASTA file used for Spectronaut
672 searches and the same fixed and variable modifications. For the raw data analysis, the default settings

673 were used, along with additional commands necessary to analyze a plexDIA experiment
674 (<https://github.com/vdemichev/DiaNN>). Specifically, the SILAC channels were registered, depending on
675 the 2- or 3-channel experiment, corresponding to Lysine and Arginine mass shifts: Lys (+4.025107 Da),
676 Lys8 (+8.014199 Da), Arg6 (+6.020129 Da), Arg10 (+10.008269 Da). Retention time translation between
677 peptides within the same elution group was enabled. Both the first ¹³C-isotopic and monoisotopic peaks
678 were included for quantification, with MS1 deconvolution level set to 2. Peptide lengths ranged from 7 to
679 30 amino acids, precursor charge states ranged from 1 to 4, and the precursor mass-to-charge (m/z) range
680 was set between 300 and 1800, with fragment ion m/z range from 200 to 1800. The precursor false
681 discovery rate (FDR) was set to 1%. Precursor matrix output tables were filtered for FDR < 0.01, as well
682 as for channel-specific (--matrix-ch-qvalue) and translated q-values < 0.01 (--matrix-tr-qvalue). The
683 match-between-runs (MBR) function in DIA-NN was enabled. The precursor-level matrices were used
684 for the downstream analyses (“report.pr_matrix_channels.tsv”).

685 **Determination of protein degradation rates from the pulse SILAC experiments**

686 Protein degradation rates reported in this manuscript were calculated using the *KdeggeR* package
687 following an algorithm based on the nls fitting in the relative light isotope abundance values (RIA_{Light}) at
688 the precursor level as described in detail previously^{5,10,11,48-50} and subsequent averaging to the protein-
689 level rates of loss and degradation rates. The main steps are described below together with the description
690 of additional options and functionalities of the package. The package will be provided via github.

691 ***Data import, formatting, and filtering.*** The precursor-level report from Spectronaut was imported and
692 the channel intensity values were filtered to remove low-intensity signals (e.g., at log₂-transformed
693 intensity < 8). Note, that this filtering significantly improves data quality in our datasets and is
694 recommended to perform in the multi-channel data analysis in Spectronaut by default, using the
695 “Minimum Log2 Precursor Quantity” quantification filter. Next, the H/L ratios were calculated and further
696 filtered based on i) valid values (e.g., at least 2 in time points 4, 8, and 12 for the A2780 datasets), ii)
697 increasing trend over the time points, and iii) outliers were detected in the first time point based on the
698 identification of significant outliers using linear regression. To do so, we fit a linear model using log-
699 transformed H/L ratios (ln(H/L +1)) from time points 4, 8, and 12. We then calculated residuals of the fit
700 per each time point, including the first time point. Grubb’s test was used as a statistical test to detect
701 significant outliers from the residual distribution in time point 1.

702 **Estimation of precursor-level k_{loss} values using the RIA method.** At each time point, the amount of heavy
703 (H) and light (L) precursor was extracted and used to calculate the relative isotopic abundance RIA_t .

704
$$RIA_t = \frac{L}{L + H}$$

705 The value of RIA_t changes over time as unlabeled proteins are gradually replaced by heavy-labeled
706 proteins throughout the experiment. This occurs because of cell division, which dilutes the unlabeled
707 proteins, and the natural turnover of intracellular proteins, where the loss rate can be described by an
708 exponential decay process.

709
$$RIA_t = RIA_0 \cdot e^{(-k_{loss} \cdot t)}$$

710

711 Where RIA_0 denotes the initial isotopic ratio and k_{loss} the rate of loss of unlabeled protein. We assumed
712 $RIA_0 = 1$, as no heavy isotope was present at $t = 0$, thus the value of RIA_t will decay exponentially from
713 1 to 0 after infinite time and used nonlinear least-squares estimation to perform the fit. As discussed before
714 ⁵, these assumptions may reduce measurement error, especially at the beginning of the experiment, where
715 isotopic ratios are less accurate.

716 **Estimation of precursor-level k_{loss} values using the NLI method.** A simpler approach to determine *de*
717 *facto* protein degradation rates is to directly calculate the rate of loss from the light peptide intensities.
718 The light peptide intensities need to be normalized using median channel sums to calculate the normalized
719 intensity values (NLI). Then, the light precursor rate of loss can be modeled using the same model and
720 assumptions as in the case of the RIA-based modeling. As we reported previously, the NLI and RIA
721 method results are strongly correlated, however, the NLI method tends to have higher variability ¹⁰.

722 **Estimation of precursor-level k_{loss} values using the HOL method.** The heavy proteins are synthesized
723 over time, leading to an increasing H/L ratio. This process is exponential because the heavy proteins are
724 gradually replacing the unlabeled (light). The H/L ratios are linearized by log-transformation and the rate
725 of incorporation of the heavy label is then estimated from a linear model.

726

727
$$\ln\left(\frac{H}{L} + 1\right) = k_{syn} \cdot t$$

728

729 In the steady-state condition, the rates of protein synthesis and degradation reach equilibrium. This means
730 that the rate at which new heavy-labeled proteins are synthesized must be balanced by the rate at which
731 proteins are degraded or turned over (k_{loss}).

732 **Estimation of protein-level k_{loss} values.** Protein-level k_{loss} values can be calculated by performing a
733 weighted average of the selected fit (e.g., RIA only) or their combination (e.g., RIA and NLI). The number
734 of data points used to estimate precursor-level k_{loss} , the variance of the fit, or both can be used as weights.

735 **Calculation of protein-level k_{deg} values.** Protein degradation rates are estimated by subtracting the cell
736 division rates (k_{cd}) to correct for the protein pool dilution caused by the exponential cell division.

737

$$738 \quad k_{deg} = k_{loss} - k_{cd}$$

739

740 However, based on our experience, the cell division rates tend to be very variable between different
741 experiments and thus the precision and accuracy tend to be low. Therefore, we decided to use a k_{cd} derived
742 from the distribution of the k_{loss} values by assuming that most k_{deg} values should be positive after the
743 correction. We herein suggest a value (k_{perc}) by subtraction of which only 1% of k_{deg} values would be
744 negative that the users may be able to estimate the k_{deg} values in cell culture derived datasets.

745

$$746 \quad k_{deg} = k_{loss} - k_{perc}$$

747 Optionally, protein half-lives from the degradation rate constant using the following formula.

$$748 \quad t_{1/2} = \frac{\ln(2)}{k_{deg}}$$

749 Note, for the results presented in this manuscript, we used the precursor k_{loss} estimation using the
750 RIA method, and then calculated the protein k_{loss} as a weighted average of the precursor-level data using
751 both number of data points and variance as the weights of the fit. The k_{deg} values were calculated by
752 subtracting the theoretical k_{perc} from the k_{loss} values.

753 **Downstream bioinformatic analysis of the drug-resistance model experiment**

754 **aCGH dataset.** Array comparative genomic hybridization (aCGH) data were downloaded from a from a
755 previous study (their Supplementary Table 1)²⁸. Protein-coding genes mapping to the regions with gene
756 copy number alterations (CNA) between the A2780 (parental) and A2780Cis (cisplatin resistant) provided

757 in the table were identified by mapping those regions to the homo sapiens Ensembl genome using the
758 bioMart R package.

759 **RNA-seq dataset.** The RNA sequencing results were downloaded from the GEO under accession
760 **GSE173201** which were published in a previous study²⁷. A table containing TPM normalized counts
761 (GSE173201_norm_counts_TPM_GRCh38.p13_NCBI.tsv) was used for all analyses presented in this
762 study. The data were filtered for transcript matching to protein-coding genes and filtered for genes with
763 at least 2 valid non-zero values (out of 3 replicates) in each condition. The TPM data were transformed
764 using the `limma::voom()` function before further statistical analysis.

765 **Proteome abundance analysis.** The protein-level pivot report tables were exported from Spectronaut v19,
766 log₂-transformed, and normalized using the `limma::normalize.cyclic.loess()` function⁵¹. The data were
767 filtered to only contain proteins quantified in at least 2 out of three experimental replicates before the
768 statistical analysis.

769 **Protein degradation analysis.** The k_{deg} values exported from the KdeggeR package were log₂-transformed
770 and filtered to only contain proteins quantified in at least 2 out of three experimental replicates before the
771 statistical analysis.

772 **Statistical analysis.** The statistical analysis was performed using the `limma`⁵² R package following the
773 standard pipeline of `lmFit()`, `contrasts.fit()`, and `eBayes()`. The `limma` results were corrected for multiple
774 testing using FDR correction using the Benjamini-Hochberg method. Cutoffs of FDR < 0.05 and an
775 absolute fold change > 1.5 were used to report significantly regulated features in the RNA-seq, protein
776 abundance, and protein degradation datasets. The moderated log₂-transformed fold changes exported from
777 the results were used in all downstream analyses.

778 **Datasets integration and correlation analysis.** The datasets were integrated based on unique gene
779 symbols. The absolute correlation analysis was performed for the A2780Cis cell line using `ids` successfully
780 quantified in all 3 layers (N = 6,221) and using average log₂ TPM, log₂ protein intensity, and log₂ k_{deg} ;
781 and Spearman's Rho was reported. The relative correlation analysis was performed using moderated log₂
782 fold changes using `ids` with valid log₂ fold change in all 3 layers (n = 6,203); and Pearson's correlation
783 was reported. For the k_{deg} ~mRNA analysis presented in Figure 5, the data were split into four groups based
784 on two parameters to perform a correlation analysis and statistical analysis using a Fisher's z-test. As for
785 the first parameter, genes affected by CNA were identified all protein-coding genes identified based on
786 the aCGH data, excluding genes encoded by the X chromosome. As for the second parameter, the genes

787 were further split based on the participation of the encoded protein in protein complexes as retrieved from
788 the Corum 4.0 database ³⁰.

789 **Functional Enrichment analyses.** A multiple gene list enrichment analysis was performed using the
790 Metascape web interface (<https://metascape.org>) ³¹ to perform the functional enrichment analysis. Four
791 lists of protein IDs were provided based on the results of the above statistical analysis (protein “up”,
792 protein “down”, k_{deg} “up”, and k_{deg} “down”), and the default parameters were used. All protein-protein
793 interactions (PPI) from the STRING database ⁵³ between the four lists of proteins were used to generate a
794 PPI network followed by the Molecular complex detection (MCODE) algorithm ⁵⁴ to identify densely
795 inter-connected clusters in the PPI network following a gene ontology (GO) enrichment analysis. The
796 resulting color-coded protein-protein interaction networks were further processed in Cytoscape (v 3.10.1)
797 to generate figures presented in Figure 6. Metascape output was also used to generate the Circos ⁵⁵ plot in
798 Figure 6. The 2D enrichment analysis ⁵⁶ presented in Figure 6 was performed using the \log_2 fold change
799 values between the A2780Cis (resistant) and A2780 (parental) cell lines at the protein abundance and
800 protein degradation (k_{deg}) level using a function provided by the Perseus ^{57,58} platform (v1.6.14.0). The
801 annotation of the gene ontology biological process (GOBP_Direct) was extracted from the DAVID
802 database ⁵⁹. In the “bubble plot” presented in Figure 6, only those categories with at least 10 protein IDs
803 and a enrichment $P < 0.01$ were visualized and further restricted to the top 25 categories with the lowest
804 P values. The size of the dots was used to reflect the number of proteins in a category.

805 **Identification of cisplatin sensitivity-related genes using DepMap.** The Dependency map (DepMap)
806 portal ³⁴ was used to perform a custom correlation analysis to identify gene expressions associated with
807 cisplatin sensitivity. A Pearson correlation was calculated between the mRNA expression dataset (Batch
808 corrected Expression Public 24Q2) and the cisplatin (CIS-DDP) sensitivity data (IC₅₀ based on Sanger
809 GDSC1) using all cell lines available (N = 154); and 414 genes were identified with a significant
810 correlation ($P < 0.01$, as reported by DepMap) and mapped to the protein abundance and degradation-
811 level data for the analysis as presented in Figure 6.

812 **Data visualization**

813 The following R packages were used for data visualization: *ggplot2*, *ggrepel*, *ggrastr*, *LSD*, and
814 *VennDiagram*. In boxplots, the box in the plot represents the interquartile range (IQR), with the lower
815 and upper edges indicating the first quartile (Q1) and third quartile (Q3), respectively, and the line inside

816 the box marking the median. Whiskers extend to the largest and smallest values within 1.5 times the IQR
817 from the edges of the box. Data points beyond this range are considered outliers and are displayed as
818 individual points. In density/violin plots, the density represents a smoothed estimate of the data
819 distribution, computed using a kernel density estimation (KDE) method; the area under the density curve
820 is equal to 1.

821 **New Data Visualization Features for Multi-Channel Workflows in Spectronaut v19.3**

822 In addition to the specialized multi-channel workflows and channel-Q-value filtering options, new
823 data visualization features for multi-channel data inspection were made available from Spectronaut v19.3
824 onward. These include e.g., scoring histograms and channel H/L ratio plots, which provide a detailed
825 overview of scoring weights across channels and the overall H/L ratio distribution across multiple samples
826 and time points, facilitating easy experiment quality control. Additionally, new protein-specific H/L plots
827 can be visualized across runs to assess the quality of individual data points.

828 **Data availability**

829 The mass spectrometry data and raw output tables as results have been deposited to the
830 ProteomeXchange Consortium via the PRIDE⁶⁰ partner repository with the following identifiers. The 2-
831 channel standard dilution sample of the A2780 cell line was deposited previously with an identifier
832 **PXD021922**. The HeLa 3-channel data were downloaded from **PXD039578**. The A2780 and A2780Cis
833 total proteome and pSILAC experiment and the pSILAC experiment in the fibroblast cell lines will be
834 available upon manuscript acceptance. The RNA sequencing results were downloaded from the GEO
835 under accession **GSE173201**. The *KdeggeR* package will be provided via github.com.

836 **Declaration of interests**

837 O.B., T.G., and L.R. are employees of Biognosys AG. Spectronaut is a trademark of Biognosys AG.

838

839 **REFERENCE**

840

841 1 Theurillat, J. P. *et al.* Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector
842 substrates in SPOP-mutant prostate cancer. *Science* **346**, 85-89 (2014).
843 <https://doi.org/10.1126/science.1250255>

- 844 2 Ming, H. *et al.* Protein degradation: expanding the toolbox to restrain cancer drug resistance. *J*
845 *Hematol Oncol* **16**, 6 (2023). <https://doi.org/10.1186/s13045-023-01398-5>
- 846 3 Venable, J. D., Dong, M. Q., Wohlschlegel, J., Dillin, A. & Yates, J. R. Automated approach for
847 quantitative analysis of complex peptide mixtures from tandem mass spectra. *Nat Methods* **1**,
848 39-45 (2004). <https://doi.org/10.1038/nmeth705>
- 849 4 Gillet, L. C. *et al.* Targeted data extraction of the MS/MS spectra generated by data-independent
850 acquisition: a new concept for consistent and accurate proteome analysis. *Mol Cell Proteomics*
851 **11**, O111 016717 (2012). <https://doi.org/10.1074/mcp.O111.016717>
- 852 5 Pratt, J. M. *et al.* Dynamics of protein turnover, a missing dimension in proteomics. *Mol Cell*
853 *Proteomics* **1**, 579-591 (2002). <https://doi.org/10.1074/mcp.m200046-mcp200>
- 854 6 Schwanhausser, B. *et al.* Global quantification of mammalian gene expression control. *Nature*
855 **473**, 337-342 (2011). <https://doi.org/10.1038/nature10098>
- 856 7 Jovanovic, M. *et al.* Immunogenetics. Dynamic profiling of the protein life cycle in response to
857 pathogens. *Science* **347**, 1259038 (2015). <https://doi.org/10.1126/science.1259038>
- 858 8 Ong, S.-E. *et al.* Stable Isotope Labeling by Amino Acids in Cell Culture, SILAC, as a Simple and
859 Accurate Approach to Expression Proteomics. *Molecular & Cellular Proteomics* **1**, 376-386 (2002).
860 <https://doi.org/10.1074/mcp.M200025-MCP200>
- 861 9 Wu, C. *et al.* Global and Site-Specific Effect of Phosphorylation on Protein Turnover.
862 *Developmental Cell* **56**, 111-124.e116 (2021).
863 [https://doi.org:https://doi.org/10.1016/j.devcel.2020.10.025](https://doi.org/https://doi.org/10.1016/j.devcel.2020.10.025)
- 864 10 Salovska, B. *et al.* Isoform-resolved correlation analysis between mRNA abundance regulation
865 and protein level degradation. *Mol Syst Biol* **16**, e9170 (2020).
866 <https://doi.org/10.15252/msb.20199170>
- 867 11 Liu, Y. *et al.* Multi-omic measurements of heterogeneity in HeLa cells across laboratories. *Nat*
868 *Biotechnol* **37**, 314-322 (2019). <https://doi.org/10.1038/s41587-019-0037-y>
- 869 12 Liu, Y. *et al.* Systematic proteome and proteostasis profiling in human Trisomy 21 fibroblast cells.
870 *Nature communications* **8**, 1212 (2017). <https://doi.org/10.1038/s41467-017-01422-6>
- 871 13 Li, W., Salovska, B., Fornasiero, E. F. & Liu, Y. Toward a hypothesis-free understanding of how
872 phosphorylation dynamically impacts protein turnover. *Proteomics* **23**, e2100387 (2023).
873 <https://doi.org/10.1002/pmic.202100387>
- 874 14 Pino, L. K., Baeza, J., Lauman, R., Schilling, B. & Garcia, B. A. Improved SILAC Quantification with
875 Data-Independent Acquisition to Investigate Bortezomib-Induced Protein Degradation. *J*
876 *Proteome Res* **20**, 1918-1927 (2021). <https://doi.org/10.1021/acs.jproteome.0c00938>
- 877 15 Salovska, B., Li, W., Di, Y. & Liu, Y. BoxCarmax: A High-Selectivity Data-Independent Acquisition
878 Mass Spectrometry Method for the Analysis of Protein Turnover and Complex Samples. *Anal*
879 *Chem* **93**, 3103-3111 (2021). <https://doi.org/10.1021/acs.analchem.0c04293>
- 880 16 Sabatier, P. *et al.* Global analysis of protein turnover dynamics in single cells. *bioRxiv*,
881 2024.2005.2030.596745 (2024). <https://doi.org/10.1101/2024.05.30.596745>
- 882 17 Derks, J. *et al.* Increasing the throughput of sensitive proteomics by plexDIA. *Nature*
883 *Biotechnology* **41**, 50-59 (2023). <https://doi.org/10.1038/s41587-022-01389-w>

- 884 18 Thielert, M. *et al.* Robust dimethyl-based multiplex-DIA doubles single-cell proteome depth via a
885 reference channel. *Mol. Syst. Biol.* **19**, e11503 (2023).
886 <https://doi.org/10.15252/msb.202211503>
- 887 19 Demichev, V., Messner, C. B., Vernardis, S. I., Lilley, K. S. & Ralser, M. DIA-NN: neural networks
888 and interference correction enable deep proteome coverage in high throughput. *Nature Methods*
889 **17**, 41-44 (2020). <https://doi.org/10.1038/s41592-019-0638-x>
- 890 20 Bruderer, R. *et al.* Optimization of Experimental Parameters in Data-Independent Mass
891 Spectrometry Significantly Increases Depth and Reproducibility of Results. *Mol Cell Proteomics*
892 **16**, 2296-2309 (2017). <https://doi.org/10.1074/mcp.RA117.000314>
- 893 21 Yu, F. *et al.* Analysis of DIA proteomics data using MSFragger-DIA and FragPipe computational
894 platform. *Nature communications* **14**, 4154 (2023). [https://doi.org/10.1038/s41467-023-39869-](https://doi.org/10.1038/s41467-023-39869-5)
895 [5](https://doi.org/10.1038/s41467-023-39869-5)
- 896 22 Bortecen, T., Müller, T. & Krijgsveld, J. An integrated workflow for quantitative analysis of the
897 newly synthesized proteome. *Nature communications* **14**, 8237 (2023).
898 <https://doi.org/10.1038/s41467-023-43919-3>
- 899 23 Parker, R. J., Eastman, A., Bostick-Bruton, F. & Reed, E. Acquired cisplatin resistance in human
900 ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug
901 accumulation. *J Clin Invest* **87**, 772-777 (1991). <https://doi.org/10.1172/jci115080>
- 902 24 Schukken, K. M. & Sheltzer, J. M. Extensive protein dosage compensation in aneuploid human
903 cancers. *Genome Res* **32**, 1254-1270 (2022). <https://doi.org/10.1101/gr.276378.121>
- 904 25 Salovska, B. & Liu, Y. Post-translational modification and phenotype. *Proteomics* **23**, e2200535
905 (2023). <https://doi.org/10.1002/pmic.202200535>
- 906 26 Muenzner, J. *et al.* Natural proteome diversity links aneuploidy tolerance to protein turnover.
907 *Nature* (2024). <https://doi.org/10.1038/s41586-024-07442-9>
- 908 27 Golan Berman, H. *et al.* Genomic Characterization of Cisplatin Response Uncovers Priming of
909 Cisplatin-Induced Genes in a Resistant Cell Line. *International journal of molecular sciences* **22**,
910 5814 (2021).
- 911 28 Prasad, M. *et al.* High definition cytogenetics and oligonucleotide aCGH analyses of cisplatin-
912 resistant ovarian cancer cells. *Genes Chromosomes Cancer* **47**, 427-436 (2008).
913 <https://doi.org/10.1002/gcc.20547>
- 914 29 Coscia, F. *et al.* Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell
915 associated proteins and functional status. *Nature communications* **7**, 12645 (2016).
916 <https://doi.org/10.1038/ncomms12645>
- 917 30 Tsitsiridis, G. *et al.* CORUM: the comprehensive resource of mammalian protein complexes-2022.
918 *Nucleic Acids Res* **51**, D539-d545 (2023). <https://doi.org/10.1093/nar/gkac1015>
- 919 31 Zhou, Y. *et al.* Metascape provides a biologist-oriented resource for the analysis of systems-level
920 datasets. *Nature communications* **10**, 1523 (2019). <https://doi.org/10.1038/s41467-019-09234-6>
- 921 32 Lai, G. M., Ozols, R. F., Young, R. C. & Hamilton, T. C. Effect of glutathione on DNA repair in
922 cisplatin-resistant human ovarian cancer cell lines. *J Natl Cancer Inst* **81**, 535-539 (1989).
923 <https://doi.org/10.1093/jnci/81.7.535>

- 924 33 Andrews, P. A., Murphy, M. P. & Howell, S. B. Metallothionein-mediated cisplatin resistance in
925 human ovarian carcinoma cells. *Cancer Chemother Pharmacol* **19**, 149-154 (1987).
926 <https://doi.org/10.1007/bf00254568>
- 927 34 Tsherniak, A. *et al.* Defining a Cancer Dependency Map. *Cell* **170**, 564-576 e516 (2017).
928 <https://doi.org/10.1016/j.cell.2017.06.010>
- 929 35 Zecha, J. *et al.* Linking post-translational modifications and protein turnover by site-resolved
930 protein turnover profiling. *Nature communications* **13**, 165 (2022).
931 <https://doi.org/10.1038/s41467-021-27639-0>
- 932 36 Zecha, J. *et al.* Peptide Level Turnover Measurements Enable the Study of Proteoform Dynamics.
933 *Mol Cell Proteomics* **17**, 974-992 (2018). <https://doi.org/10.1074/mcp.RA118.000583>
- 934 37 Kluever, V. *et al.* Protein lifetimes in aged brains reveal a proteostatic adaptation linking
935 physiological aging to neurodegeneration. *Sci Adv* **8**, eabn4437 (2022).
936 <https://doi.org/10.1126/sciadv.abn4437>
- 937 38 Petelski, A. A. *et al.* Multiplexed single-cell proteomics using SCoPE2. *Nat Protoc* **16**, 5398-5425
938 (2021). <https://doi.org/10.1038/s41596-021-00616-z>
- 939 39 Welter, A. S. *et al.* Combining Data Independent Acquisition With Spike-In SILAC (DIA-SiS)
940 Improves Proteome Coverage and Quantification. *Molecular & Cellular Proteomics* **23**, 100839
941 (2024). [https://doi.org:https://doi.org/10.1016/j.mcpro.2024.100839](https://doi.org/https://doi.org/10.1016/j.mcpro.2024.100839)
- 942 40 Chepyala, S. R. *et al.* JUMPt: Comprehensive Protein Turnover Modeling of In Vivo Pulse SILAC
943 Data by Ordinary Differential Equations. *Anal. Chem.* **93**, 13495-13504 (2021).
944 <https://doi.org/10.1021/acs.analchem.1c02309>
- 945 41 Behrens, B. C. *et al.* Characterization of a cis-diamminedichloroplatinum(II)-resistant human
946 ovarian cancer cell line and its use in evaluation of platinum analogues. *Cancer Res* **47**, 414-418
947 (1987).
- 948 42 Eastman, A. & Schulte, N. Enhanced DNA repair as a mechanism of resistance to cis-
949 diamminedichloroplatinum(II). *Biochemistry* **27**, 4730-4734 (1988).
950 <https://doi.org/10.1021/bi00413a022>
- 951 43 Collins, B. C. *et al.* Multi-laboratory assessment of reproducibility, qualitative and quantitative
952 performance of SWATH-mass spectrometry. *Nature communications* **8**, 291 (2017).
953 <https://doi.org/10.1038/s41467-017-00249-5>
- 954 44 Mehnert, M., Li, W., Wu, C., Salovska, B. & Liu, Y. Combining Rapid Data Independent Acquisition
955 and CRISPR Gene Deletion for Studying Potential Protein Functions: A Case of HMGN1.
956 *Proteomics* **19**, e1800438 (2019). <https://doi.org/10.1002/pmic.201800438>
- 957 45 Bruderer, R. *et al.* Analysis of 1508 Plasma Samples by Capillary-Flow Data-Independent
958 Acquisition Profiles Proteomics of Weight Loss and Maintenance. *Mol Cell Proteomics* **18**, 1242-
959 1254 (2019). <https://doi.org/10.1074/mcp.RA118.001288>
- 960 46 Meier, F. *et al.* diaPASEF: parallel accumulation–serial fragmentation combined with data-
961 independent acquisition. *Nature Methods* **17**, 1229-1236 (2020).
962 <https://doi.org/10.1038/s41592-020-00998-0>
- 963 47 Skowronek, P. *et al.* Rapid and In-Depth Coverage of the (Phospho-)Proteome With Deep
964 Libraries and Optimal Window Design for dia-PASEF. *Molecular & Cellular Proteomics* **21** (2022).
965 <https://doi.org/10.1016/j.mcpro.2022.100279>

- 966 48 Claydon, A. J. & Beynon, R. Proteome dynamics: revisiting turnover with a global perspective. *Mol*
967 *Cell Proteomics* **11**, 1551-1565 (2012). [https://doi.org:10.1074/mcp.O112.022186](https://doi.org/10.1074/mcp.O112.022186)
- 968 49 Doherty, M. K., Hammond, D. E., Clague, M. J., Gaskell, S. J. & Beynon, R. J. Turnover of the human
969 proteome: determination of protein intracellular stability by dynamic SILAC. *J Proteome Res* **8**,
970 104-112 (2009). [https://doi.org:10.1021/pr800641v](https://doi.org/10.1021/pr800641v)
- 971 50 Rost, H. L. *et al.* TRIC: an automated alignment strategy for reproducible protein quantification
972 in targeted proteomics. *Nat Methods* **13**, 777-783 (2016). [https://doi.org:10.1038/nmeth.3954](https://doi.org/10.1038/nmeth.3954)
- 973 51 Smyth, G. K. in *Bioinformatics and Computational Biology Solutions Using R and Bioconductor*
974 (eds Robert Gentleman *et al.*) 397-420 (Springer New York, 2005).
- 975 52 Ritchie, M. E. *et al.* limma powers differential expression analyses for RNA-sequencing and
976 microarray studies. *Nucleic Acids Res* **43**, e47 (2015). [https://doi.org:10.1093/nar/gkv007](https://doi.org/10.1093/nar/gkv007)
- 977 53 Szklarczyk, D. *et al.* STRING v11: protein-protein association networks with increased coverage,
978 supporting functional discovery in genome-wide experimental datasets. *Nucleic acids research*
979 **47**, D607-D613 (2019). [https://doi.org:10.1093/nar/gky1131](https://doi.org/10.1093/nar/gky1131)
- 980 54 Bader, G. D. & Hogue, C. W. An automated method for finding molecular complexes in large
981 protein interaction networks. *BMC Bioinformatics* **4**, 2 (2003). [https://doi.org:10.1186/1471-](https://doi.org/10.1186/1471-2105-4-2)
982 [2105-4-2](https://doi.org/10.1186/1471-2105-4-2)
- 983 55 Krzywinski, M. *et al.* Circos: an information aesthetic for comparative genomics. *Genome Res* **19**,
984 1639-1645 (2009). [https://doi.org:10.1101/gr.092759.109](https://doi.org/10.1101/gr.092759.109)
- 985 56 Cox, J. & Mann, M. 1D and 2D annotation enrichment: a statistical method integrating
986 quantitative proteomics with complementary high-throughput data. *BMC Bioinformatics* **13**
987 **Suppl 16**, S12 (2012). [https://doi.org:10.1186/1471-2105-13-S16-S12](https://doi.org/10.1186/1471-2105-13-S16-S12)
- 988 57 Tyanova, S. & Cox, J. Perseus: A Bioinformatics Platform for Integrative Analysis of Proteomics
989 Data in Cancer Research. *Methods Mol Biol* **1711**, 133-148 (2018). [https://doi.org:10.1007/978-](https://doi.org/10.1007/978-1-4939-7493-1_7)
990 [1-4939-7493-1_7](https://doi.org/10.1007/978-1-4939-7493-1_7)
- 991 58 Tyanova, S. *et al.* The Perseus computational platform for comprehensive analysis of
992 (prote)omics data. *Nature Methods* **13**, 731-740 (2016). [https://doi.org:10.1038/nmeth.3901](https://doi.org/10.1038/nmeth.3901)
- 993 59 Sherman, B. T. *et al.* DAVID: a web server for functional enrichment analysis and functional
994 annotation of gene lists (2021 update). *Nucleic Acids Res* (2022).
995 [https://doi.org:10.1093/nar/gkac194](https://doi.org/10.1093/nar/gkac194)
- 996 60 Perez-Riverol, Y. *et al.* The PRIDE database and related tools and resources in 2019: improving
997 support for quantification data. *Nucleic Acids Res* **47**, D442-D450 (2019).
998 [https://doi.org:10.1093/nar/gky1106](https://doi.org/10.1093/nar/gky1106)
999






Figure 2











Figure 5

